[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-acetaldehyde | 223253-70-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: [4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-acetaldehyde
• 英文别名: 2-[4-(2-Propan-2-yloxyphenyl)piperazin-1-yl]acetaldehyde
• CAS: 223253-70-1
• 化学式: C₁₅H₂₂N₂O₂
• 分子量: 262.352
• InChiKey: UTIVOSLRXNIWNY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-acetaldehyde 在 4-二甲氨基吡啶 、 甲基磺酰氯 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 1-{(E)-5-[4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-2-oxo-pent-3-enyl}-piperidin-2-one
  参考文献：
  名称：

  Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists

  摘要：

  A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00169-4
• 作为产物：
  描述：

  2-(1-methylethoxy)phenyl-1-piperazine 在 草酰氯 、 potassium carbonate 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 [4-(2-Isopropoxy-phenyl)-piperazin-1-yl]-acetaldehyde
  参考文献：
  名称：

  Novel heterocycles as selective α1-adrenergic receptor antagonists

  摘要：

  A novel series of aryl piperazine substituted heterocycles has been synthesized and identified as antagonists of the alpha (1a) adrenergic receptor (alpha (1a)-AR), which has been implicated in benign prostatic hyperplasia (BPH). These compounds selectively inhibit binding to the alpha (1a)-AR with K(i)s as low as 2.1 nM. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00472-8

文献信息

• Heterocycles useful in the treatment of benign prostatic hyperplasia
  申请人：Ortho-McNeil Pharmaceutical, Inc.

  公开号：US06384035B1

  公开（公告）日：2002-05-07

  This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

  这项发明涉及一系列异环取代哌嗪的化合物I的制药组合物，以及用于其制备的中间体。该发明的化合物选择性地抑制与α-1a肾上腺能受体的结合，该受体已被认为与良性前列腺增生有关。因此，这些化合物在治疗这种疾病方面具有潜在的用途。
• Novel arylpiperazines as selective α 1 -adrenergic receptor antagonists
  作者：Xiaobing Li、William V Murray、Linda Jolliffe、Virginia Pulito

  DOI：10.1016/s0960-894x(00)00169-4

  日期：2000.5

  A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.
• Novel heterocycles as selective α1-adrenergic receptor antagonists
  作者：Xiaobing Li、Kathleen A McCoy、William V Murray、Linda Jolliffe、Virginia Pulito

  DOI：10.1016/s0960-894x(00)00472-8

  日期：2000.10

  A novel series of aryl piperazine substituted heterocycles has been synthesized and identified as antagonists of the alpha (1a) adrenergic receptor (alpha (1a)-AR), which has been implicated in benign prostatic hyperplasia (BPH). These compounds selectively inhibit binding to the alpha (1a)-AR with K(i)s as low as 2.1 nM. (C) 2000 Elsevier Science Ltd. All rights reserved.